ADRB1 and familial dilated cardiomyopathy: Because of the limited and insufficiently convincing available data (mostly case reports) regarding the potential benefit of therapeutic plasma exchange for GPCR-AAb-positive patients, its use for β1AR-AAb-positive patients with DCM still cannot be recommended [1].